Kolexia
Coudert Bruno Oncologie médicale
Coudert Bruno
Oncologie médicale
Centre Georges-François Leclerc
Dijon, France
152 Activités
4 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinomes Adénocarcinome Métastase tumorale Récidive tumorale locale Tumeurs du sein triple-négatives

Collaborateurs

Voir plus
Arnould Laurent
Arnould Laurent
Centre Georges-François Leclerc, Dijon, France
Fumoleau Pierre
Fumoleau Pierre
Clcc Institut Curie, Paris, France
Favier Laure
Favier Laure
Centre Georges-François Leclerc, Dijon, France
Foucher Pascal
Foucher Pascal
Hôpital François Mitterrand, Dijon, France

Industries

Voir plus
Roche
4 collaboration(s)
Dernière en 2021
Amgen
1 collaboration(s)
Dernière en 2020
Parexel
1 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Frontiers in oncology   10 janvier 2024
PREDIGOSTEO: Osteopathy and Prevention of Gastrointestinal Side Effects of the Adjuvant Treatment FEC in Women Treated in Day Hospital for Breast Cancer
Essai Clinique (Centre Georges-François Leclerc)   16 octobre 2023
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Breast cancer (Tokyo, Japan)   10 août 2023
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Molecular cancer   29 juillet 2023
BioCAST: French Biological Observatory on Lung Cancer in Never Smokers
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   22 mai 2023
CHACRY-1501: Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Essai Clinique (Centre Oscar-Lambret)   13 février 2023
Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
Breast (Edinburgh, Scotland)   04 février 2023
CheckMate057: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Essai Clinique (BMS)   13 janvier 2023
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017): An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Essai Clinique (BMS)   22 novembre 2022
Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.
PloS one   19 avril 2022